I dont understand the industry as well as i would like, but my understanding is that Mayne is focused on the US specifically because drugs are so much more expensive their than anywhere else. It does sell/manufacture to other countries as well, but the focus of capital is the US.
If the US did fix their health system to be like normal countries i expect it would hurt a lot, i dont expect Trump to fix anything, but he could still cause damage to the industry by trying, it is a risk.
From an ethics point of view, participating in the market by introducing generics (which are cheaper) can only help, and i havent seen anything to suggest that Mayne uses extreme pricing like the owners of the Epi-Pen.
Mayne is a significant shareholder in Hedgepath which has a trialling a drug which targets some types of cancer. They are building manufacturing plant in US, and also makes a fair bit from lab services, its not a company just sitting back exploiting IP, they do real work as well.
- Forums
- ASX - By Stock
- MYX
- Quantifying downside risks
Quantifying downside risks, page-3
-
- There are more pages in this discussion • 265 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MYX (ASX) to my watchlist
|
|||||
Last
$4.78 |
Change
-0.330(6.46%) |
Mkt cap ! $406.6M |
Open | High | Low | Value | Volume |
$5.03 | $5.06 | $4.77 | $920.9K | 187.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 3095 | $4.74 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$4.85 | 986 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 3095 | 4.740 |
1 | 986 | 4.730 |
1 | 986 | 4.720 |
1 | 986 | 4.700 |
1 | 986 | 4.690 |
Price($) | Vol. | No. |
---|---|---|
4.850 | 986 | 1 |
4.860 | 986 | 1 |
4.870 | 986 | 1 |
4.880 | 3679 | 2 |
4.890 | 986 | 1 |
Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |